The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
Washington, DC
- Tweets 29,737
- Following 616
- Followers 102,684
- Likes 430
Celldex monoclonal antibody rebounds with a pair of phase 3 wins for chronic skin condition fiercebiotech.com/biotech/ce…
1
1
10
3,503
Novartis secures new radioligand in $900M deal fiercebiotech.com/biotech/no…
1
4
26
4,681
Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential $1 billion multi-year pact that will task Boehringer with validating tumor-specific targets. fiercebiotech.com/biotech/bo…
4
18
3,566
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes fiercebiotech.com/biotech/ro…
2
14
3,543
A phase 3 study of Otsuka and Ionis’ ALS prospect hit its primary endpoint, positioning the partners to talk to regulators about expedited approvals. fiercebiotech.com/biotech/ot…
1
4
17
4,201
Telix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to Novartis’ Lutathera and a radiopharmaceutical supply network. fiercebiotech.com/biotech/an…
1
1
9
3,534
Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of sleep disorders and into broader patient populations. fiercebiotech.com/biotech/pi…
3
2
14
3,701
China is aiming to account for at least 25% of first-in-class drugs as part of a five-year push to cement its emerging status in innovative R&D. fiercebiotech.com/biotech/ch…
1
4
8
3,397
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope fiercebiotech.com/biotech/re…
7
4,109
Xenon pauses phase 3 depression trials after psychosis events fiercebiotech.com/biotech/xe…
10
3,832
BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data fiercebiotech.com/biotech/br…
1
4
20
5,792
After a run of dealmaking, Gilead CEO Daniel O'Day told Fierce that any future M&A activity will only be done to complement the existing strategy. fiercebiotech.com/biotech/it… @GileadSciences
1
20
4,527
A phase 2 trial of Johnson & Johnson’s JNJ-5120 has missed its primary endpoint, denting the prospects of the Contineum Therapeutics-partnered depression drug candidate. fiercebiotech.com/biotech/jj…
2
10
3,937
Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations. fiercebiotech.com/biotech/li…
4
15
6,277
Novo’s rebrand got off to a shaky start with news the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug. fiercebiotech.com/biotech/no…
4
5
4,019
Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal fiercebiotech.com/biotech/bi…
2
10
4,080
Massachusetts governor makes pre-election pitch to biotechs amid warning early-stage start-ups are "dying" fiercebiotech.com/biotech/ma…
1
5
3,900
Kura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment. fiercebiotech.com/biotech/ku…
1
1
5
3,873
Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail fiercebiotech.com/biotech/ev…
1
4
3,719
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win fiercebiotech.com/biotech/ro…
5
23
4,723